 Odonate Therapeutics NASDAQ:ODT was upgraded by Zacks Investment Research from a hold rating to a buy rating in a research report issued on Thursday, Zacks.com reports. The brokerage currently has a 36.00 target price on the stock. Zacks Investment Researchs target price points to a potential upside of 14.87 from the companys current price. According ... 